Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by jdstoxon Oct 17, 2018 11:28pm
105 Views
Post# 28824545

RE:RE:RE:Lawler’s lab

RE:RE:RE:Lawler’s lab These scientists all have their own pursuits, regardless. Most of those pursuits are academic in nature, which was true in Lawler's case, if I recall correctly.

As for digitel, he spends a lot of time rehashing old stuff and trying to hold the company's feet to the fire over everything it's ever done or said. I would ask him why he didn't mention that Lawler was a part of that Harvard PR over three years ago. He was afraid to straight out say it, for reasons about which I have previously opined.

Bioasis needed to get control of its own story. To me it meant that we needed to advance xB3 within our own development programs. That is exactly what Bioasis started doing a few months ago. Those plans have been articulated, have been modified with increasing knowledge and scientific input, are progressing, and that progress should become more evident as time passes.

BD deals have also been described as important elements of the company's future. I have nothing to add on that subject.

jdstox

Bullboard Posts